Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Thyroid. 2022 Oct;32(10):1220-1228. doi: 10.1089/thy.2022.0234. Epub 2022 Sep 22.
Radioactive iodine lobar ablation (RAILA) of the contralateral thyroid lobe has been suggested as an alternative to completion thyroidectomy in patients of differentiated thyroid cancer (DTC) who underwent initial hemithyroidectomy. However, data on long-term outcomes are scarce. In this study, we intended to describe the long-term outcomes of RAILA versus completion thyroidectomy in a cohort of low-risk DTC patients. Data of patients with low-risk DTC who underwent initial hemithyroidectomy, and were subsequently treated with either completion thyroidectomy or RAILA between 1996 and 2015, were collected and analyzed. The treatment outcomes included ablation rate, recurrence rate, recurrence-free survival (RFS), and adverse events, and were validated by propensity score matching analysis. Of the 1243 patients (median age: 34 years, range: 5-78) with low-risk DTC, 514 patients underwent upfront RAILA while 729 patients underwent completion thyroidectomy followed by remnant ablation. The ablation rate following the first radioactive iodine (I) cycle was 75.3% [95% confidence interval (CI) 71.3-78.9] in the RAILA group versus 84.1% [CI 81.2-86.6] in the completion thyroidectomy group ( < 0.001). Over median follow-up of 11.4 years (interquartile range: 8.3-15.8), the recurrence rates between the two groups were not significantly different (1.6% [CI 0.7-3.2] vs. 1.0% [CI 0.4-2.1], respectively, = 0.343). The product limit estimate of RFS at 10 years was 98.6% [CI 97.6-99.6%] in the RAILA group versus 99.1% [CI 98.3-99.9%] in the completion thyroidectomy group ( = 0.391). The outcomes in 497 matched pairs generated through propensity score analysis were similar. None of the patients in the RAILA group experienced permanent hypocalcemia or recurrent laryngeal nerve palsy, while the corresponding rates in the completion thyroidectomy group were 10/729 (1.4%) ( = 0.006) and 5/729 (0.7%) ( = 0.080), respectively. Radiation thyroiditis was seen in 25/514 (4.9%) patients in the RAILA group versus 3/729 (0.4%) in the completion thyroidectomy group ( < 0.001). Upfront RAILA is seen to be a noninvasive, safe, and effective alternative to surgical completion thyroidectomy in low-risk DTC patients in the absence of macroscopic malignancy in the remaining thyroid lobe.
放射性碘叶切除术(RAILA)已被建议作为分化型甲状腺癌(DTC)患者初次甲状腺叶切除术的替代方案,这些患者在初次甲状腺叶切除术后行甲状腺全切除术。然而,关于长期结果的数据仍然很少。在这项研究中,我们旨在描述低危 DTC 患者队列中 RAILA 与甲状腺全切除术的长期结果。
收集并分析了 1996 年至 2015 年间接受初次甲状腺叶切除术、随后接受甲状腺全切除术或 RAILA 治疗的低危 DTC 患者的数据。治疗结果包括消融率、复发率、无复发生存率(RFS)和不良事件,并通过倾向评分匹配分析进行了验证。
在 1243 例低危 DTC 患者(中位年龄 34 岁,范围 5-78 岁)中,514 例患者行初始 RAILA,729 例患者行甲状腺全切除术加残余组织消融。首次放射性碘(I)周期后的消融率在 RAILA 组为 75.3%(95%可信区间 71.3-78.9),在甲状腺全切除术组为 84.1%(95%可信区间 81.2-86.6)( < 0.001)。在中位随访 11.4 年(四分位距 8.3-15.8)期间,两组之间的复发率无显著差异(分别为 1.6%[95%可信区间 0.7-3.2]和 1.0%[95%可信区间 0.4-2.1], = 0.343)。RAILA 组 10 年 RFS 的乘积限估计值为 98.6%(97.6-99.6%),甲状腺全切除术组为 99.1%(98.3-99.9%)( = 0.391)。通过倾向评分分析生成的 497 对匹配对的结果相似。RAILA 组无一例患者发生永久性低钙血症或喉返神经麻痹,而甲状腺全切除术组分别为 10/729(1.4%)( = 0.006)和 5/729(0.7%)( = 0.080)( = 0.006)。RAILA 组 25/514(4.9%)患者出现放射性甲状腺炎,而甲状腺全切除术组 3/729(0.4%)( < 0.001)。
在剩余甲状腺叶无肉眼恶性肿瘤的情况下,RAILA 作为低危 DTC 患者甲状腺全切除术的一种非侵入性、安全且有效的替代方法。